Pleiotropic Effects of Fenofibrate

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2009 Feb 10

PMID 19199978

Citations 8

Authors

V Tsimihodimos

E Liberopoulos

M Elisaf

Affiliations

Soon will be listed here.

Abstract

Fenofibrate represents the most commonly used fibric acid derivative. The drug exerts its metabolic effects by modulating the expression of several genes involved in lipoprotein metabolism. In addition, numerous studies suggest that fenofibrate may also affect the progression of the atherosclerotic process by several lipid-independent mechanisms. This review considers the clinical pharmacology of fenofibrate and the current evidence on the pleiotropic effects of this fibric acid derivative.

Citing Articles

Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate.

Januszewski A, Young H, Ong K, Li L, OConnell R, Lyons T J Diabetes Investig. 2024; 15(11):1663-1668.

PMID: 39171747 PMC: 11527820. DOI: 10.1111/jdi.14290.

Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in mice fed a high-fat diet.

Zhang Y, Jia X, Liu Y, Yu W, Si Y, Guo S Front Nutr. 2022; 9:971581.

PMID: 36172518 PMC: 9511108. DOI: 10.3389/fnut.2022.971581.

Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes.

Frazier R, Mehta R, Cai X, Lee J, Napoli S, Craven T Kidney Int Rep. 2019; 4(1):94-102.

PMID: 30596172 PMC: 6308372. DOI: 10.1016/j.ekir.2018.09.006.

The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review.

Malur P, Menezes A, DiNicolantonio J, OKeefe J, Lavie C Mo Med. 2018; 114(6):464-471.

PMID: 30228666 PMC: 6139978.

A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

Filippatos T Cardiovasc Drugs Ther. 2012; 26(3):245-55.

PMID: 22592524 PMC: 3368211. DOI: 10.1007/s10557-012-6394-0.